Jinli Chen
Papers
1
Total Citations
2
H-Index
1
About
Dr. Jinli Chen is a leading urologic oncologist whose research focuses on the intersection of obesity, biomarker accuracy, and prostate cancer prognostication. Her most influential work introduces a novel concept: body mass weighted prostate-specific antigen (PSA) levels. In her landmark 2024 paper, Dr. Chen demonstrates that adjusting PSA for a patient’s body mass index significantly improves the prediction of locally advanced prostate cancer following prostatectomy. This contribution addresses a critical clinical gap—the well-documented inverse relationship between obesity and PSA concentration, which can mask aggressive disease in overweight men. By proposing these weight-adjusted markers, she provides a more precise tool for risk stratification, potentially reducing underdiagnosis in obese populations. While her work is still accumulating citations (2 to date), its immediate relevance to precision oncology and personalized screening is evident. Dr. Chen’s research bridges endocrinology and surgical oncology, offering a practical, data-driven solution to a long-standing diagnostic challenge. Her ongoing investigations continue to refine how body composition metrics can enhance the utility of standard cancer biomarkers, positioning her as an emerging voice in the fight against prostate cancer disparities.
Research Focus
Key Achievements
Top Papers
- 1